Skip to main content
Equibles
CBIO logo

CBIO · Crescent Biopharma, Inc. · Metrics

Track CBIO — free

Use CBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.82 -0.32 (-2.44%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$476.19M
Shares
37.14M
Volume · Oct 23 397.81K Avg daily vol (3M) 350.98K

CBIO metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.82
Market cap
$476.19M

Price action

20 metrics
Price change (1W)
+8.3%
Price change (30D)
-8.4%
Price change (3M)
-21.3%
Price change (6M)
-48.3%
Price change (YTD)
+8.1%
Price change (1Y)
+0.2%
Trailing year
Price change (5Y)
—
52-week high
$26.98
52-week low
$8.94
Change from 52-week high
-52.5%
Change from 52-week low
+43.4%
Annualized volatility
80.3%
Annualized volatility (3M)
72.8%
Beta
1.0
RSI (14D)
39.0
Price vs SMA 50
-19.8%
Price vs SMA 200
-19.0%
Avg volume (3M)
350,981
Relative volume
1.1
Average dollar volume
$5.65M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
37.14M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
40.1×
reciprocal yield 2.5%
P / book
2.9
reciprocal yield 34.3%
FCF yield
-15.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-41.3×
EV / revenue historical average (5Y)
-41.3×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-26

Profitability

9 metrics
Gross margin
—
Operating margin
-1,407.5%
Trailing 12 months
Net margin
-1,419.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$168.47M
Net income (TTM)
−$96.03M
Trailing 12 months
Diluted EPS (TTM)
$-59.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-66.61
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-62.58
Operating cash flow per diluted share (TTM)
$-56.20
Free cash flow per diluted share (TTM)
$-56.23
Capital expenditures per diluted share (TTM)
$0.03
R&D per diluted share (TTM)
$30.51
Stock compensation per diluted share (TTM)
$6.61
Book value per share
$7.37

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$11.88M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.2%
Year over year · more shares
Revenue CAGR (3Y)
+424.9%
Revenue CAGR (5Y)
+1.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-58.8%
Return on assets
-52.5%
Debt / equity
—
Current ratio
9.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$73.62M
Quick ratio
9.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$171.59M
Latest balance sheet
Cash & equivalents
$171.59M
Total assets
$182.76M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$72.68M
Capital expenditures (TTM)
$939,000
R&D (TTM)
$152.67M
SG&A (TTM)
$6.60M
Stock compensation (TTM)
$14.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
80
13F filer change QoQ
+20
Institutional ownership
78.4%
Conviction holders (share of 13F filers)
3.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+9.6%
Holder tenure
4.0
Price vs estimated holder cost
+25.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.1%

Short interest

3 metrics
Short interest
12.9%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$285,501
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 9 filings 9 filers Visit website Investor relations